Biotechnology company Leucid Bio has established proof-of-concept for CAR-T therapy LEU011 for the treatment of solid tumours. LEU011 is being evaluated in the ongoing AERIAL trial, but data has established proof-of-concept by demonstrating key biological activity through evidence of encouraging pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Analysis… Read More
New data on Molecular Partners’ radiotherapy candidate MP0712 shows targeted delivery into cancer tumours. MP0712 is being developed for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The candidate, which targets DLL3, showed potential to deliver radiotherapy treatment to tumours with… Read More
Research showing the Covid-19 mRNA vaccine boosts the immune system’s response to cancer has been described as ‘extraordinary’. Scientists at the University of Florida and the University of Texas MD Anderson Cancer Center found patients with advanced lung or skin cancer lived significantly longer when receiving the… Read More
eBioMedicine, a Lancet Discovery Science journal, has published Intensity Therapeutics’ Phase I/II IT-01 clinical study manuscript for the treatment of metastatic or refractory cancers. According to the data, in heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following… Read More
Biotechnology company MaaT Pharma has announced preclinical results for its drug candidate MaaT034, including promising anti-tumour efficacy results and immune activation. MaaT034, a first-in-class co-cultured full ecosystem product, is designed to optimise intestinal microbiome functions and improve patient responses to immunotherapy in combination with Immune Checkpoint Inhibitors (ICIs). The… Read More
Researchers have discovered a ‘handbrake’ mechanism controlling how cells respond to cancer drugs, which could reshape understanding of cancer drug resistance. The breakthrough research, led by scientists from the University of Oxford and the Research Centre for Molecular Medicine, Austria, demonstrates how the enzyme NUDT5 acts as a molecular… Read More
Scientists have successfully used the first bioengineered bone marrow model to carry out cancer research, offering a new method which does not rely on animal models. The breakthrough, made by researchers at the University of Glasgow, represents an important step forward in being able to uncover insights into leukaemia without the… Read More
CellBxHealth, the company specialising in circulating tumour cell (CTC) solutions, has presented encouraging results on cell visualisation and biomarker analysis, which could shape antibody-drug conjugate (ADC) therapy. The results, presented at the World ADC conference in San Diego, US, demonstrate successful cell visualisation and biomarker analysis across ADC targets… Read More
Eisai and Merck (MSD outside of the US and Canada) have announced that in a Phase III trial, Lenvima (lenvatinib) plus Keytruda (pembrolizumab) with transarterial chemoembolisation (TACE) did not achieve statistical significance for overall survival (OS) compared to TACE alone. The LEAP-012 trial evaluated the combination in… Read More
Cambritaxestat, a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), has met its primary endpoint in a Phase Ib trial. Cambritaxestat, an oral autotaxin (ATX) inhibitor, was evaluated in patients with previously untreated mPDAC. The treatment demonstrated safety, tolerability and anti-tumour responses, with data presented at the European Society… Read More
A new AI model developed by Google and Yale researchers has revealed a potential novel cancer therapy pathway. The AI model ‘Cell2Sentence-Scale 27B’ analyses single-cell RNA data using large language models and is designed to be a bridge to make single-cell data accessible, or interpretable, by AI. Read More
A trio of French organisations across pharma, government and academia have partnered with the aim of accelerating immunotherapy for oncology, inflammation, and autoimmunity research. OSE Immunotherapeutics, Inserm Transfert and Nantes University have signed a strategic partnership which will combine academic research with industrial expertise to bring more immunotherapies… Read More
A new study in Structure, a Cell Press journal demonstrates that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation (TPD). The authors say DCAF2 presents an exciting opportunity to deliver tumour-targeted protein degraders given its frequent overexpression in various types… Read More
Memorial Sloan Kettering Cancer Center (MSK) and Quantoom Biosciences have executed a non-exclusive research license and supply agreement to support the development of personalised cancer therapies using Quantoom’s lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002. Under the agreement, MSK will use Ncapsulate QCX-002, an LNP delivery chemistry… Read More
Great Ormond Street Hospital Charity (GOSH Charity) has joined Cancer Research Horizons and LifeArc as a core partner to help drive innovation in children’s and young people’s cancer treatment, drug discovery consortium C-Further has announced. C-Further is an international consortium of drug discovery and development researchers, clinicians,… Read More
AecorBio has successfully completed an equity financing round of $1.5m (£1.1m), enabling the company to investigate its lead peptide candidate FT-002a to treat advanced prostate cancer. AecorBio, formerly known as HBC Immunology Inc, will use the financing to enable an Investigational New Drug (IND) application with the US Food and… Read More
